- Home
- LGVN
LGVN
Longeveron Inc.
as 12-18-2024 12:39pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 28.4M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 325.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $21.30 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,852,000 | Revenue Growth: | 141.46% |
| Revenue Growth (this year): | 161.78% | Revenue Growth (next year): | 40.89% |
Stock Insider Trading Activity of Longeveron Inc. (LGVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baluch Khoso | LGVN | Director | Dec 2 '24 | Sell | $2.07 | 1,250 | $2,588.13 | 23,750 |
Latest Longeveron Inc. News
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 hours ago
Longeveron to Present at Biotech Showcase 2025
TipRanks
11 days ago
Longeveron initiated with a Buy at Roth MKM
GlobeNewswire
14 days ago
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
GlobeNewswire
16 days ago
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
Simply Wall St.
a month ago
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
Zacks Small Cap Research
a month ago
LGVN Highlights Potential Groundbreaking Treatments
GlobeNewswire
a month ago
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
MT Newswires
a month ago
Longeveron Names Devin Blass Chief Technology Officer
Compare LGVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.